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T
ype 1 diabetes is conventionally thought to result
from T-cell–mediated autoimmune destruction
of pancreatic -cells (1–3). Experimental and
clinical evidence accumulated over the past two
decades indicates that T-cells play a critical role in the
pathogenesis of type 1 diabetes in both humans and the
nonobese diabetic (NOD) mouse model of this disease (4).
Indeed, the important contribution of T-cells toward the
pathogenesis of type 1 diabetes has been supported not
only by a variety of physiologic and histological studies
but, in addition, through a number of immunotherapeutic-
based studies involving selective targeting of T-cells (4,5).
More recently, it has been shown that B-cells also play an
important role in type 1 diabetes development (6), since
NOD mice deﬁcient in these cells do not develop insulitis
or overt diabetes (7), and that the depletion of B-cells with
anti-CD20 antibody prevents disease (8).
Apart from diabetogenic T- and B-cells, emerging evi-
dence suggests that macrophages are involved in the ﬁnal
stage of autoimmune-mediated -cell destruction (9,10).
For example, after monocyte depletion, passively trans-
ferred diabetogenic T-cells fail to induce diabetes, and
activated macrophages can directly kill -cells in vitro
(10). However, direct evidence that activated monocytes/
macrophages kill -cells is minimal or lacking, depending
on one’s perspective. In the current issue of Diabetes,
Martin et al. (11), using multiple transgenic mouse models,
provide convincing evidence that monocytes can be re-
cruited to pancreatic islets when the chemokine CCL2 is
expressed transgenically in -cells and that these immune
system cells are capable of destroying -cells, resulting in
diabetes in the absence of mature T- and B-cells. There-
fore, this observation adds monocytes/macrophages to the
growing list of immune cells involved in islet cell destruc-
tion in type 1 diabetes.
There are two distinct phases for autoimmune-mediated
diabetes: insulitis and diabetes. In the early stages of
insulitis, mixed leukocytes including activated macro-
phages, B-cells, T-cells, and NK cells are attracted to the
islets by chemokines. Chemokines are chemoattractant
proteins (12,13) produced by cells in response to infection
or cell damage (13). Leukocytes, such as lymphocytes,
monocytes, and NK cells, expressing the appropriate re-
ceptors, migrate toward the source of chemokine produc-
tion. Chemokines are subdivided into four subfamilies (C,
CC, CXC, and CX3C) based on the location of the ﬁrst
conserved NH2-terminal cysteine residues (13). The largest
group is the CC family, where two cysteine residues are
immediately adjacent to each other.
CCL2, also known as monocyte chemoattractant pro-
tein-1 (MCP-1), is a CC chemokine produced by lympho-
cytes, monocytes, endothelial cells, and other cells in
response to inﬂammatory stimuli (14). Through its recep-
tor CCR2, MCP-1/CCL2 potently attracts monocytes, T-
cells, and NK cells. Although MCP-1 is expressed in normal
human and rodent islets (15), transgenic mice overex-
pressing MCP-1 under control of the insulin promoter
develop an intense insulitis, but overt diabetes was not
seen in early studies (16). The temporal pattern of MCP-1
and other chemokine expression correlates with the pro-
gression of insulitis and -cell destruction in NOD mice
(17).
Despite substantial indirect evidence that CCL2 is in-
volved in the pathogenesis of type 1 diabetes, its precise
role in the development of insulitis and islet cell destruc-
tion is incompletely understood. Martin et al. (11) add to
the accumulating evidence that CCL2 production and
numbers of circulating monocytes play a more impor-
tant role in the onset of diabetes than was previously
suspected.
The investigators demonstrate that monocytes/macro-
phages are recruited in a concentration-dependent manner
to the islets by transgenic expression of CCL2 in -cells
under the control of the insulin promoter. The CCL2-
mediated monocyte recruitment requires the CCL2 recep-
tor (CCR2), since deletion of CCR2 in RIPCCL2 mice
abolishes homing to the islets. Strikingly, and in contrast
to previous studies (16,18), transgenic mice displaying
high MCP-1 expression and serum MCP-1 levels not only
develop insulitis but also go on to islet cell destruction and
clinical diabetes. The explanation for this apparent dis-
crepancy may lie both in the relatively high level of MCP-1
expressed (up to 1.4 ng/ml in the serum) and in the fact
that MCP-1 production in the Martin et al. (11) study was
restricted to islets, whereas expression was more wide-
spread in the study of Rutledge et al. (18). Importantly, to
assess the inﬂuence of T- and B-cells, Martin et al. bred the
RIPCCL2 transgene onto a Rag-1
/ background to gener-
ate mice expressing CCL2 in -cells in the absence of
mature T- and B-cells. Remarkably, the hybrid mice devel-
oped diabetes with a similar time course to that of
immunocompetent Rag1
/ controls.
Thus, although diabetogenic T- and B-cells may be
central to the pathogenesis of type 1 diabetes under
“physiological” conditions (2,19), the Martin et al. study
extends data from several other laboratories (9,10,16,20),
suggesting that monocytes/macrophages also may play a
critical role. Most current therapies, such as the induction
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2922 DIABETES, VOL. 57, NOVEMBER 2008of immunoregulatory T-cells, costimulatory blockade, and
T- or B-cell depletion with anti-CD3 or -CD20 antibodies
(5,8,19,21), target the lymphocyte arm of the autoimmune
response to islets. One implication of the current study is
that therapy directed at the antigen-presenting cells also
may be effective. Indeed, a variety of MCP-1/CCL2 inhibi-
tors are under development, and it has been shown that
anti-CCL2 therapy can reverse other autoimmune disor-
ders in animal models, such as murine demyelinating
disease (22) and lupus nephritis (23). The Martin et al.
study may provide a conceptual framework for the design
of monocyte therapy aimed at interrupting insulitis and
the destruction of pancreatic -cells. This study may
also provide a rationale for monitoring CCL2 levels and
circulating monocyte numbers in the blood as parame-
ters to predict the disease onset and monitor the disease
progression (Fig. 1).
However, caution should be exercised in evaluating and
interpreting this study. Transgenic overexpression of
CCL2 in -cells does not necessarily reproduce the defect
in human type 1 diabetes, although pancreatic islet tissue
from patients with recent-onset type 1 diabetes exhibits
macrophages and dendritic cells inﬁltrating the islets and
the production of inﬂammatory cytokines (tumor necrosis
factor- and interleukin-1) (24). Moreover, in view of
the redundancy of chemokine pathways, the efﬁcacy of
disrupting a single chemokine pathway remains to be
determined. Nevertheless, further investigation of the
potential for monocyte therapy of type 1 diabetes seems
warranted.
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FIG. 1. Arrow indicates a circulating
monocyte on peripheral blood smear.
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